Publications PostersEORTC-NCI-AACR 2018Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell linesRobert C. DoebeleThe hypoxia-activated EGFR/HER2 inhibitor Tarloxotinib is activated by the plasma membrane reductase STEAP4, Abstract Number 422Adam V. PattersonTargeting tumor hypoxia with tarloxotinib improves the therapeutic efficacy of immune checkpoint blockadeAdam V. PattersonInternational Conference on Tumor Microenvironment and Cellular Stress 2018Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignanciesAdam V. PattersonEORTC-NCI-AACR 2017Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertionsRobert C. DoebeleSelected Reference PublicationsHypoxia-activated prodrugs: paths forward in the era of personalised medicineBr J Cancer, May 10 2016Structural, biochemical and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancerSci Transl Med, December 18 2013EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristicsMolecular Cancer Therapeutics, February 2013EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsThe Lancet, January 2012The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci U S A, February 12 2008Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, June 1 2004
